دورية أكاديمية
أعرض في EDS

Symptomatic Heart Failure and Clonal Hematopoiesis-Related Mutations in Patients With Acute Myeloid Leukemia.

التفاصيل البيبلوغرافية
العنوان: Symptomatic Heart Failure and Clonal Hematopoiesis-Related Mutations in Patients With Acute Myeloid Leukemia.
المؤلفون: Kang Y; Division of Cardiovascular Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Lefebvre B; Division of Cardiovascular Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Pamies IM; Division of Cardiovascular Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Gill SI; Division of Hematology and Oncology Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Doucette AG; Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Denduluri S; Division of Cardiovascular Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Smith AM; Division of Cardiovascular Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Division of Hematology and Oncology Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., McCurdy S; Division of Hematology and Oncology Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Luger S; Division of Hematology and Oncology Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Carver J; Division of Cardiovascular Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Scherrer-Crosbie M; Division of Cardiovascular Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Marielle.Scherrer-Crosbie@pennmedicine.upenn.edu.
المصدر: The American journal of cardiology [Am J Cardiol] 2024 Sep 01; Vol. 226, pp. 9-17. Date of Electronic Publication: 2024 Jul 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Excerpta Medica Country of Publication: United States NLM ID: 0207277 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1913 (Electronic) Linking ISSN: 00029149 NLM ISO Abbreviation: Am J Cardiol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Excerpta Medica
مواضيع طبية MeSH: Heart Failure*/genetics , Heart Failure*/epidemiology , Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/epidemiology , Clonal Hematopoiesis*/genetics , Mutation* , DNA Methyltransferase 3A* , DNA (Cytosine-5-)-Methyltransferases*/genetics, Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Adult ; Incidence ; Dioxygenases ; DNA-Binding Proteins/genetics ; Risk Factors ; Repressor Proteins/genetics ; Proto-Oncogene Proteins/genetics
مستخلص: Clonal hematopoiesis of indeterminate potential (CHIP) is a common risk factor for hematologic malignancies and cardiovascular diseases. This study aimed to investigate the association between CHIP-related mutations and symptomatic heart failure (HF) in patients diagnosed with acute myeloid leukemia (AML). A total of 563 patients with newly diagnosed AML who underwent DNA sequencing of bone marrow before treatment were retrospectively investigated. Cox proportional hazard regression models and Fine and Gray's subdistribution hazard regression models were used to assess the association between CHIP-related mutations and symptomatic HF. A total of 79.0% patients had at least 1 CHIP-related mutation; the most frequent mutations were DNMT3A, ASXL1, and TET2. A total of 51 patients (9.1%) developed symptomatic HF. The incidence of symptomatic HF was more frequent in patients with DNMT3A mutations (p <0.01), with a 1-year cumulative incidence of symptomatic HF in patients with DNMT3A mutations of 11.4%, compared with 3.9% in patients with wild-type DNMT3A (p <0.01). After adjustment for age and anthracyclines dose, DNMT3A mutations remained independently correlated with HF (hazard ratio 2.32, 95% confidence interval 1.26 to 4.29, p = 0.01). In conclusion, in patients with AML, the presence of DNMT3A mutations was associated with a twofold increased risk for symptomatic HF, irrespective of age and anthracyclines use.
Competing Interests: Declaration of competing interest The authors have no competing interests to declare.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
References: N Engl J Med. 2014 Dec 25;371(26):2477-87. (PMID: 25426838)
Nat Genet. 2011 Dec 04;44(1):23-31. (PMID: 22138693)
J Clin Oncol. 2011 Jul 20;29(21):2889-96. (PMID: 21670448)
N Engl J Med. 2012 Mar 22;366(12):1079-89. (PMID: 22417203)
J Am Coll Cardiol. 2021 Apr 13;77(14):1747-1759. (PMID: 33832602)
JACC Basic Transl Sci. 2020 Feb 24;5(2):196-207. (PMID: 32140625)
JAMA Cardiol. 2019 Jan 1;4(1):25-33. (PMID: 30566180)
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):E1490-E1499. (PMID: 28167789)
EBioMedicine. 2022 Apr;78:103964. (PMID: 35339897)
Circulation. 2018 Feb 27;137(9):961-972. (PMID: 29483172)
N Engl J Med. 2014 Dec 25;371(26):2488-98. (PMID: 25426837)
Leuk Lymphoma. 2023 Feb;64(2):445-453. (PMID: 36331544)
JAMA Netw Open. 2024 Jan 2;7(1):e2353244. (PMID: 38270950)
Leukemia. 2017 Jun;31(6):1286-1295. (PMID: 27881874)
Exp Hematol. 2020 Mar;83:95-104. (PMID: 31891750)
Circ Res. 2018 Jul 20;123(3):335-341. (PMID: 29728415)
N Engl J Med. 2010 Dec 16;363(25):2424-33. (PMID: 21067377)
Eur Heart J. 2020 Feb 21;41(8):933-939. (PMID: 31504400)
JACC CardioOncol. 2019 Dec;1(2):208-217. (PMID: 32905430)
Nat Genet. 2016 Oct;48(10):1193-203. (PMID: 27526324)
JAMA Cardiol. 2024 Jan 1;9(1):16-24. (PMID: 37938837)
J Am Coll Cardiol. 2021 Jul 6;78(1):42-52. (PMID: 34210413)
Leuk Res. 2012 Sep;36(9):1128-33. (PMID: 22749068)
JACC CardioOncol. 2022 Mar 15;4(1):38-49. (PMID: 35492819)
Blood. 2005 Feb 15;105(4):1734-41. (PMID: 15494427)
Clin Cancer Res. 2018 Oct 1;24(19):4633-4642. (PMID: 29703819)
Clin Cancer Res. 2015 Apr 1;21(7):1614-20. (PMID: 25609058)
Nat Cardiovasc Res. 2023 Jan 16;2:144-158. (PMID: 36949957)
Nature. 2014 Feb 20;506(7488):328-33. (PMID: 24522528)
J Thromb Haemost. 2024 Jun;22(6):1569-1582. (PMID: 38382738)
Pediatr Blood Cancer. 2011 Sep;57(3):467-72. (PMID: 21280201)
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. (PMID: 24030381)
معلومات مُعتمدة: R01 HL130539 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: DNMT3A; acute myeloid leukemia; clonal hematopoiesis of indeterminate potential; heart failure
المشرفين على المادة: EC 2.1.1.37 (DNA Methyltransferase 3A)
0 (DNMT3A protein, human)
EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)
EC 1.13.11.- (TET2 protein, human)
0 (ASXL1 protein, human)
EC 1.13.11.- (Dioxygenases)
0 (DNA-Binding Proteins)
0 (Repressor Proteins)
0 (Proto-Oncogene Proteins)
تواريخ الأحداث: Date Created: 20240707 Date Completed: 20240818 Latest Revision: 20240820
رمز التحديث: 20240820
مُعرف محوري في PubMed: PMC11330721
DOI: 10.1016/j.amjcard.2024.06.033
PMID: 38972534
قاعدة البيانات: MEDLINE
الوصف
تدمد:1879-1913
DOI:10.1016/j.amjcard.2024.06.033